Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Overweight patients with type 2 diabetes continue to experience the benefits of bariatric surgery up to nine years after the procedure, according to new research from Cleveland Clinic's Bariatric & Metabolic Institute, published online in the journal, Annals of Surgery.
Prior research has shown that bariatric surgery effectively treats diabetes and reduces cardiovascular risk factors, but few studies have reported the long-term metabolic effects of bariatric surgery. This trial shows that obese patients with type 2 diabetes continue to improve or reverse their diabetes, as well as reduce their cardiovascular risk factors, nine years after the procedure.
Cleveland Clinic researchers also identified the factors that result in a higher rate of long-term diabetes remission. Long-term weight loss, a shorter duration of diabetes prior to surgery (less than five years), and undergoing gastric bypass surgery compared to adjustable gastric banding are the biggest predictors of sustained diabetes remission.
"Uncontrolled diabetes can lead to serious complications such as heart and kidney disease. Only about half of diabetics in the United States currently have acceptable control of their blood glucose level," said lead investigator Stacy Brethauer, M.D., a bariatric surgeon at the Cleveland Clinic Bariatric & Metabolic Institute. "Our study, however, shows that 80 percent of the diabetic patients still control their blood glucose five years after their bariatric surgery. Additionally, nearly one-third of gastric bypass patients had normal blood glucose levels off medication for over five years after surgery. This study confirms that the procedure can offer durable remission of diabetes in some patients and should be considered as an earlier treatment option for patients with uncontrolled diabetes."
Cleveland Clinic researchers have been at the forefront of research in this field. They led the groundbreaking STAMPEDE (Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently) trial published in The New England Journal of Medicine in 2012. The STAMPEDE trial was the first to show that bariatric surgery is more effective than medical therapy in controlling diabetes in obese patients. Additional pioneering research in the field includes a Cleveland Clinic-led substudy of STAMPEDE, published in Diabetes Care in 2013, which found that gastric bypass surgery reverses diabetes by uniquely restoring pancreatic function in moderately obese patients with uncontrolled type 2 diabetes.
With the publication of this new trial, Cleveland Clinic researchers further advance the body of research on bariatric surgery as a treatment option for patients with uncontrolled diabetes.
The retrospective study analyzed data on 217 patients with type 2 diabetes who underwent bariatric surgery between 2004 and 2007 and had at least five years follow-up. The patients were divided into three groups: 162 patients underwent gastric bypass surgery, 32 had the gastric banding procedure done, and 23 underwent sleeve gastrectomy.
Researchers used strict criteria to define glycemic control, including an HbA1c level of less than 6 percent, which is a more aggressive target than the American Diabetes Association (ADA) guidelines. ADA recommends an HbA1c target of 7 percent.
At a median follow-up of six years, data show that diabetes remission occurred in 50 percent of patients after bariatric surgery. Specifically, 24 percent of patients sustained complete remission of their diabetes with a blood sugar level of less than six percent without diabetes medications, and another 26 percent achieved partial remission; 34 percent of all patients improved their long-term diabetes control compared to presurgery status. As expected, the patients who received gastric bypass experienced the highest rates of weight loss and diabetic remission.
The study shows significant reductions in the number of diabetic medications used in the long-term follow-up. There was a 50 percent reduction in the number of patients requiring insulin therapy in the long term and a 10-fold increase in the number of patients requiring no medications. In addition, the data show patients significantly reduced their cardiovascular risk factors according to the Framingham Risk Score. Diabetic nephropathy, characterized by high protein levels in the urine, improved or stabilized as well.
No funding was provided for this research. Dr. Brethauer is a consultant and speaker for Ethicon Endo-Surgery and a speaker for Covidien.
Annals of Surgery: October 2013 - Volume 258 - Issue 4 - p 628–637 doi: 10.1097/SLA.0b013e3182a5034b
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Diabetes category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Clinic, Cleveland. "The long-term effects of bariatric surgery in patients with type 2 diabetes." Medical News Today. MediLexicon, Intl., 23 Sep. 2013. Web.
5 Dec. 2013. <http://www.medicalnewstoday.com/releases/266391>
Clinic, C. (2013, September 23). "The long-term effects of bariatric surgery in patients with type 2 diabetes." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/266391.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.